Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):106–113. doi: 10.1097/QAI.0b013e3181a4f9c4

Figure 1. Health and Cost Outcomes of Alternative HAART Regimens.

Figure 1

Life expectancy and lifetime costs of alternative HAART strategies. Letters correspond to strategies in Table 1 (A, 2 regimens; B, 3 regimens with triple NRTI as initial therapy; C, 3 regimens with second generation bPI). Monitoring strategy is represented as either CD4 counts only (CD4) or CD4 and viral loads (VL). Strategy B is strictly dominated when only CD4 counts are available (it is more costly and less effective than other strategies), and dominated by extended dominance when viral loads are available (it is more costly and less effective than some combination of A and C). Solid lines connect the cost-effective strategies within a given monitoring strategy, and the dotted line connect the cost-effective strategies regardless of monitoring strategy.